Results of the ex vivo screening indicated an apparent MAPK/PI3K signaling pathway switch in the tumor cells based on the high sensitivity of the cells to mTOR inhibition, MEK inhibition and partial response also to antifolate abitrexate, BRAF and EGFR inhibition. This evidence concerns the gene MTOR and neoplasm.